We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVN
76
DELISTED
Trevena, Inc.
TRVN
$2.65M 0.03%
720
– –
ENTA icon
77
Enanta Pharmaceuticals
ENTA
$392M
$2.52M 0.02%
75,357
– –
SYRS
78
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.49M 0.02%
20,447
– –
OSIR
79
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$2.45M 0.02%
499,193
– –
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.34M 0.02%
413,697
– –
CBIO
81
Crescent Biopharma
CBIO
$637M
$2.33M 0.02%
3,812
– –
CRBP icon
82
Corbus Pharmaceuticals
CRBP
$201M
$2.2M 0.02%
+8,671
New +$1.99M
NBRV
83
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.09M 0.02%
1,400
– –
KPTI icon
84
Karyopharm Therapeutics
KPTI
$44.5M
$2.04M 0.02%
14,466
– –
SYRE icon
85
Spyre Therapeutics
SYRE
$9.39B
$1.76M 0.02%
16,169
– –
FSTX
86
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.75M 0.02%
+54,825
New +$2.01M
NVIV
87
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$1.68M 0.02%
21
– –
CNCE
88
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.57M 0.02%
152,964
-164,012
-52% -$1.5M
JUNO
89
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.51M 0.01%
80,000
– –
SCYX icon
90
SCYNEXIS
SCYX
$50.7M
$1.49M 0.01%
5,845
– –
FLGT icon
91
Fulgent Genetics
FLGT
$548M
$1.45M 0.01%
125,000
– –
MYOK
92
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.29M 0.01%
100,000
– –
QURE icon
93
uniQure
QURE
$3.36B
$1.29M 0.01%
230,000
– –
MCRB icon
94
Seres Therapeutics
MCRB
$45.8M
$1.24M 0.01%
6,250
– –
CLCD
95
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$1.1M 0.01%
30,310
– –
AIXC
96
AIxCrypto Holdings Inc
AIXC
$22.7M
$1.08M 0.01%
3
– –
PRQR icon
97
ProQR Therapeutics
PRQR
$330M
$1.04M 0.01%
212,698
-647,766
-75% -$3.34M
MDWD icon
98
MediWound
MDWD
$171M
$1.03M 0.01%
32,286
– –
PTN
99
Palatin Technologies
PTN
$17.2M
$1.03M 0.01%
1,640
– –
FPRX
100
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$964K 0.01%
19,247
– –
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2016 Portfolio in Review

As of Q4 2016, Julian Baker held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Julian Baker's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Julian Baker added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Julian Baker's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Julian Baker fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Julian Baker's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Julian Baker opened 7 new positions and closed 7 in Q4 2016.
  • Julian Baker's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.